SLCTR/2015/005已完成1 期
A phase I study of the safety/ possible toxicity of a novel Ayurvedic preparation, Sudarshana Suspension.
HETC Project, Ministry of Higher Education0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age group of 18-60 years at the time of enrollment, of either sex with weight less than 60kg
- •2.Those who have no known systemic disorders, such as hypertension, diabetes mellitus, hypercholesterolemia and chronic arthritis
- •3. Those who have no history of drug allergy.
- •4.Those who have no history of intolerance to Sudarshana Powder or similar compounds
- •5. Women should be non pregnant and non breast feeding.
- •6. Only those who can write and read languages of English or Sinhala.
排除标准
- •Concurrent treatment with any Ayurveda or Western medicine
研究者
相似试验
已完成
不适用
WT1 TCR gene therapy for leukaemia: a phase I/II safety and toxicity study (WT1 TCR-001)CancerISRCTN11622375niversity College London (UCL) (UK)7
已完成
不适用
A Phase I safety, toxicity and biomarker study of peri-operative sorafenib treatment in patients undergoing radiofrequency ablation (RFA) for liver metastases of colorectal cancerLiver neoplasm100198151002765610019818Liver cancerNL-OMON31730niversitair Medisch Centrum Utrecht12
招募中
1 期
A Phase I/II trial to determine the Safety, Toxicity and Efficacy of Iodine-131-Rituximab and the Histone Deacetylase Inhibitor Panobinostat in Relapsed and Refractory Indolent B-cell LymphomaRelapsed and Refractory Indolent B-cell LymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaACTRN12612000746831Peter MacCallum Cancer Centre30
终止
1 期
This study is examining the safety and tolerability of a new drug (Everolimus) in combination with chemotherapy in the treatment of relapsed adult acute lymphobastic leukaemiaacute lymphobastic leukaemia (ALL)Cancer - Leukaemia - Acute leukaemiaACTRN12610000405011Australasian Leukaemia and Lymphoma Group20
进行中（未招募）
1 期
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to AssessAdverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid TumorsAdvanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)JPRN-jRCT2031210468Yajima Yoko109